Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22551881 | 0.85 | KMT2A (0.40) | NPC1KMT2ARAB9ATDP1L3MBTL1 | |
| SCHEMBL22655334 | 0.81 | BMPR1A (0.40) | NPC1KMT2ARAB9ABMPR1BBMPR1A | |
| SCHEMBL5196773 | 0.81 | ACVRL1 (0.41) | NPC1KMT2ARAB9AACVRL1ACVR1 | |
| SCHEMBL16064383 | 0.81 | KMT2A (0.36) | NPC1KMT2ARAB9ATDP1L3MBTL1 | |
| SCHEMBL19951562 | 0.80 | MEN1 (0.38) | KMT2ABMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL9609775 | 0.78 | ALDH1A1 (0.55) | KMT2ABMPR1BBMPR1ATGFBR1ACVRL1 | |
| SCHEMBL252411 | 0.78 | KMT2A (0.41) | NPC1KMT2ARAB9ACNR1BMPR1B | |
| SCHEMBL20197193 | 0.77 | BMPR1B (0.38) | BMPR1BBMPR1ATGFBR1ACVRL1ACVR1 | |
| SCHEMBL2608967 | 0.77 | MAPT (0.46) | KMT2ACNR1BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL2534037 | 0.75 | KMT2A (0.39) | NPC1KMT2ARAB9ATDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | PROTHENA BIOSCIENCES INC | 2025-02-27 | — | — | US | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| CN-118843626-A | Heterocyclic compounds as DYRK1A inhibitors | 普罗塞纳生物科学有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| EP-4444421-A2 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| WO-2023107723-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| CN-111433195-B | Pyridone derivatives and their use as selective ALK-2 inhibitors | 诺华股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| CN-110072861-B | Disubstituted pyrazoles for the treatment of diseases | FGH生物科技公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2906539-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| US-8513232-B2 | Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands | CEPHALON, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2250176-B1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON INC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| EP-2250176-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009097567-A1 | SUBSTITUTED SPIROCYCLIC PIPERIDINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066318-A1 | HETEROCYCLIC COMPOUNDS AS DYRK1A INHIBITORS | DYRK1A, DYRK2, DYRK1B | NPC1 3120/4885KMT2A 549/4885RAB9A 731/4885 |
| US-20110071131-A1 | Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | NPC1 1888/4885KMT2A 840/4885RAB9A 1092/4885 |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | NPC1 1001/4885KMT2A 3036/4885RAB9A 1127/4885 |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, PYGB | NPC1 2002/4885KMT2A 1058/4885RAB9A 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.